Boston Scientific Corporation $BSX Shares Bought by Sigma Planning Corp

Sigma Planning Corp grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,113 shares of the medical equipment provider’s stock after purchasing an additional 508 shares during the quarter. Sigma Planning Corp’s holdings in Boston Scientific were worth $764,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific during the first quarter valued at $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the first quarter worth about $27,000. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Truist Financial increased their price objective on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Robert W. Baird lifted their target price on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $123.77.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

BSX opened at $100.05 on Friday. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a market capitalization of $148.26 billion, a price-to-earnings ratio of 53.50, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The business has a 50 day moving average price of $100.09 and a two-hundred day moving average price of $102.45. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.